Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01057199
First received: January 26, 2010
Last updated: June 5, 2010
Last verified: June 2010
  Purpose

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at biomarkers in cell samples from patients with acute myeloid leukemia.


Condition Intervention
Leukemia
Genetic: RNA analysis
Genetic: gene expression analysis
Genetic: mutation analysis
Genetic: protein expression analysis
Other: fluorescence activated cell sorting
Other: laboratory biomarker analysis

Study Type: Observational
Official Title: Critical Role of MicroRNA-34a and MicroRNA-194 in Acute Myeloid Leukemia With CEBPA Mutations

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Significance of regulation of microRNA-34a and microRNA-194 by C/EBPα during granulopoiesis [ Designated as safety issue: No ]
  • Relationship between overexpression of microRNA-34a and microRNA-194 in myeloid progenitors with C/EBPα mutations and granulocytic differentiation [ Designated as safety issue: No ]
  • Downregulation of E2F3 by microRNA-34a and microRNA-194 during granulopoiesis [ Designated as safety issue: No ]
  • Role of microRNA-34a and microRNA-194 in myeloid cell proliferation [ Designated as safety issue: No ]

Estimated Enrollment: 6
Study Start Date: January 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To determine the significance of regulation of microRNA-34a and microRNA-194 by C/EBPα during granulopoiesis in patients with acute myeloid leukemia with CEBPA mutations.
  • To determine whether overexpression of micro RNA-34a and microRNA-194 in myeloid progenitors with C/EBPα mutations leads to granulocytic differentiation.
  • To examine how microRNA-34a and microRNA-194 downregulate E2F3 during granulopoiesis.
  • To determine the role of microRNA-34a and microRNA-194 in myeloid cell proliferation.

OUTLINE: Cryopreserved cell samples are collected for laboratory analysis, including mutation analysis, gene expression analysis, RNA analysis, and fluorescence-activated cell sorting (FACS) analysis.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of acute myeloid leukemia with CEBPA mutations

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01057199

Sponsors and Collaborators
Children's Oncology Group
Investigators
Principal Investigator: Soheil Meshinchi, MD Fred Hutchinson Cancer Research Center
  More Information

Additional Information:
No publications provided

Responsible Party: Gregory H. Reaman, Children's Oncology Group - Group Chair Office
ClinicalTrials.gov Identifier: NCT01057199     History of Changes
Other Study ID Numbers: CDR0000664229, COG-AAML10B13
Study First Received: January 26, 2010
Last Updated: June 5, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
adult acute myeloid leukemia
childhood acute myeloid leukemia/other myeloid malignancies

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on October 20, 2014